Combination studies with gemcitabine in the treatment of non-small-cell lung cancer

British Journal of Cancer

Volumn 78, Issue SUPPL. 1, 1998, Pages 15-19

  Steward, W P ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Combination therapy; Gemcitabine; Non small cell lung cancer

Indexed keywords

CISPLATIN; GEMCITABINE; IFOSFAMIDE; NAVELBINE; RADIOSENSITIZING AGENT;

ALOPECIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; HOSPITALIZATION; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RADIOSENSITIZATION; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MIDDLE AGED; VINBLASTINE;

EID: 0031854767     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.749     Document Type: Article

References (30)

1. Abratt RP, Bezwoda WR, Goedhals L and Hacking DJ (1997) Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 15: 744-749
2. Anton A, Artal A, Carrato A, Diaz-Fernandez N, González Larriba JL, Vadell C, Masutti B, Montalar J, Aranda E, Barnetto I, Tarazona Y and López-Martín E (1997) Gemcitabine plus cisplatin in advanced NSCLC: final phase II results. Proc Am Soc Clin Oncol 16: 461a
3. Armand JP, Ducreux M, Mahjoubi M, Abigerges D, Bugat R, Chabot P, Herait P, de Forni M and Rougier P (1995) CPT-II (Irinotecan) in the treatment of colorectal cancer. Eur J Cancer 31A: 1283-1287
4. Cardenal F, Resell R, Antón A, Lomas M, Alberola V, Barnetto I, Carrato A, Massuti B, Lianes P, Montalar J, Vadell C, Gonzalez JL and López-Martin E (1997) Gemcitabine + cisplatin in advanced non-small cell lung cancer patients: preliminary randomized phase III results. Proc Am Soc Clin Oncol 16: 458a
5. Carmichael J, Allerheiligen S and Walling J (1995) A phase I/II study of gemcitabine (GEM) and carboplatin (CBP) in NSCLC. Proc Am Soc Clin Oncol 14: 351
6. Clarke SJ, Jackman AL and Harrap KR (1991) Antimetabolites in cancer chemotherapy. Adv Exp Med Biol 309: 7-13
7. Comella P, Panza N, Frasci G, Nicolella GP, Natale M, Pacilio G, Gravina A and Comella G (1997) Gemcitabine (GEM)-cisplatin (CDDP)-vinorelbine (VNR) combination in advanced non-small-cell lung cancer (NSCLC). A phase II randomized study. Proc Am Soc Clin Oncol 16: 449a
8. Crinò L, Clerici M and Figioli F (1995) Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol 6: 347-353
9. Crinò L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, Salvati F, Cruciani G, Dogliotti L, Pucci F, Paccagnella A, Adamo V, Altavilla G, Incoronato P, Trippetti M, Mosconi AM, Santucci A, Sorbolini S, Oliva C and Tonato M (1997) Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 15: 297-303
10. Eberhard W, Wilke H, Manegold CH, Gatzemeier U, Blatter J, Drings P and Seeber S (1995) Phase I dose finding study of gemcitabine (GEM) and ifosfamide (IFO) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14: 351
11. Goor C, Scalliet P, Van Meerbeek J, Galdermans D, Groen HJM, Van der Leest AHD, Westerink H and Peolman M (1996) A phase II study combining gemcitabine with radiotherapy in Stage III NSCLC. Ann Oncol 7: 101
12. Heinemann V, Hertel LW, Grindey GB and Plunkett W (1988) Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxyclidine and 1-β-D-arabino-furanosylcytosine. Cancer Res 48: 4024-4031
13. Jolivet J, Cowan KH and Curt GA (1983) The pharmacology and clinical use of methotrexate. N Engl J Med 309: 1094-1104
14. Kaye SB (1994) Gemcitabine: current status of phase I and II trials. J Clin Oncol 12: 1527-1531
15. Keating MJ, McCredie KB, Bodey GP, Smith TL, Gehan E and Freircich BJ (1982) Improved prospects for long-term survival in adults with acute myelogenous leukemia. J Am Med Assoc 248: 2481-2486
16. Krajnik G, Mohn-Staudner A, Marhold F, Malayeri R, Zöchbauer S, Kummer F, Greil R, Huber H and Pirker R for the Austrian Association for the Study of Lung Cancer (1997) Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial. Clin Pharmacol 16: 206a
17. Lawrence TS, Chang EY, Hahnn TM, Hertel LW and Shewach DS (1996) Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 34: 867-872
18. Manegold CH, Eberhard W, Wilke H, Gatzemeier U, Chomy F, Chomy P, Khayat D, Blatter J and Drings P (1996) Phase II study of gemcitabine (GEM) and ifosfamide (IFO) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 15: 380a
19. Merriman RL, Hertel LW, Schultz RM, Houghton PJ, Rutherford PG, Tanzer LR, Boder GB and Grindey GB (1996) Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs 14: 243-247
20. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN, Krakoff IH and Hong WK (1993) Phase II study of taxol in patients with untreated non-small-cell lung cancer. J Natl Cancer Ins: 85: 388-394
21. Perigaud C, Gosselin G and Imbach J (1992) Nucleoside analogues as chemotherapeutic agents: a review. Nucleosides Nucleotides 11: 903-945
22. Peters GJ, Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM and Braakhuis BJM (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 4: 72-79
23. Roberts JJ and Pascoe JM (1972) Cross-linking of complementary strands of DNA in mammalian cells by antitumor platinum compounds. Nature 235: 282-284
24. Rustum YM, Harstrick A, Cao S, Vanhoefer U, Yin MB, Wilke H and Seeber S (1997) Thymidylale synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 15: 389-400
25. Sandler AB, Ansari R, McClean J, Fisher W, Dorr A and Einhorn LH (1995) A Hoosier Oncology Group phase II study of gemcitabine plus cisplatin in non-small cell lung cancer. Proc Am Soc Clin Oncol 14:357
26. Sandler A, Crinò, Steward WP and Abratt RP (1996) Extended survival in stage III and IV non-small cell lung cancer (NSCLC) patients treated with gemcitabine plus monthly cisplatin. Ann Oncol 7: 91
27. Schoenike SE and Dana WJ (1990) Ifosfamide and mesna. Clin Pharmacol 9: 179-191
28. Shepherd FA, Burkes R, Cormier Y, Crump M, Feld R, Strack T and Schulz M (1996) Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematical modelling to determine maximum-tolerable dose. J Clin Oncol 14: 1655-1662
29. Shewach DS, Hahn TM, Chang E, Hertel LW and Lawrence TS (1994) Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 54: 3218-3223
30. Steward WP, Dunlop DJ, Dabouis G, Lacroix H and Talbot D (1996) Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results. Semin Oncol 23: 43-47